Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Biomaterials. 2021 Apr;271:120735. doi: 10.1016/j.biomaterials.2021.120735. Epub 2021 Feb 24.
The central vision-threatening event in glaucoma is dysfunction and loss of retinal ganglion cells (RGCs), thought to be promoted by local tissue deformations. Here, we sought to reduce tissue deformation near the optic nerve head by selectively stiffening the peripapillary sclera, i.e. the scleral region immediately adjacent to the optic nerve head. Previous scleral stiffening studies to treat glaucoma or myopia have used either pan-scleral stiffening (not regionally selective) or regionally selective stiffening with limited access to the posterior globe. We present a method for selectively stiffening the peripapillary sclera using a transpupillary annular light beam to activate methylene blue administered by retrobulbar injection. Unlike prior approaches to photocrosslinking in the eye, this approach avoids the damaging effects of ultraviolet light by employing red light. This targeted photocrosslinking approach successfully stiffened the peripapillary sclera at 6 weeks post-treatment, as measured by whole globe inflation testing. Specifically, strain was reduced by 47% when comparing treated vs. untreated sclera within the same eye (n = 7, p=0.0064) and by 54% when comparing the peripapillary sclera of treated vs. untreated eyes (n = 7, p<0.0001). Post-treatment characterization of RGCs (optic nerve axon counts/density, and grading), retinal function (electroretinography), and retinal histology revealed that photocrosslinking was associated with some ocular toxicity. We conclude that a transpupillary photocrosslinking approach enables selective scleral stiffening targeted to the peripapillary region that may be useful in future treatments of glaucoma.
青光眼导致中央视力受损的主要原因是视网膜神经节细胞(RGC)功能障碍和丧失,目前认为这是由局部组织变形引起的。在这里,我们试图通过选择性地增强视盘周围巩膜(即紧邻视神经头部的巩膜区域)来减少视神经头部附近的组织变形。以前的巩膜增强治疗青光眼或近视的研究要么使用全巩膜增强(非区域选择性),要么使用对后眼球有限进入的区域选择性巩膜增强。我们提出了一种使用经瞳孔环形光束选择性增强视盘周围巩膜的方法,该方法通过球后注射来激活亚甲蓝。与以前在眼睛中进行光交联的方法不同,这种方法通过使用红光避免了紫外线的破坏性影响。这种靶向光交联方法在治疗后 6 周成功地增强了视盘周围巩膜,通过整个眼球膨胀测试进行测量。具体来说,在同一眼中,治疗组与未治疗组之间的巩膜(n=7,p=0.0064)的应变减少了 47%,在治疗组与未治疗组的视盘周围巩膜之间(n=7,p<0.0001)的应变减少了 54%。对 RGC(视神经轴突计数/密度和分级)、视网膜功能(视网膜电图)和视网膜组织学进行的治疗后特征分析表明,光交联与一些眼部毒性有关。我们得出结论,经瞳孔光交联方法可实现针对视盘周围区域的选择性巩膜增强,这可能对未来的青光眼治疗有用。